Alnylam Licenses IP Covering RNAi Applications in Vaccines | GenomeWeb

Alnylam Pharmaceuticals said this week that it has licensed intellectual property related to RNAi applications in vaccine development from the Mount Sinai School of Medicine and the University of Queensland in Australia.

Specific terms of the arrangements were not disclosed.

The company said it is collaborating with researchers at Mount Sinai to develop microRNA-based attenuated influenza viruses that have benefits over live attenuated influenza vaccines.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.